Mammotome | Advancing Breast Biopsy Technology
corporate

Media Contacts

Erica Bednar, 513-864-9383
erica.bednar@devicormedical.com

Press Releases

May 1st, 2014
DEVICOR MEDICAL PRODUCTS COMPLETES ACQUISITION OF THE HYDROMARK® BREAST BIOPSY MARKER PORTFOLIO

Deal strengthens global breast biopsy company’s leadership position

Cincinnati, Ohio – May 01, 2014– Devicor® Medical Products, Inc. (Devicor), a portfolio company of GTCR, a leading private equity firm, announced today the acquisition of the HydroMARK® breast biopsy marker portfolio and related assets from Biopsy Sciences, LLC.

"We are proud to add HydroMARK to our existing family of Mammotome® markers," said Devicor CEO Tom Daulton. "Combining HydroMARK with our existing MammoMARK®, MammoStar® and MicroMARK® products allows us to offer customers a complete portfolio of tissue markers that meets all of their breast biopsy marking needs."

HydroMARK was developed by Dr. John Fisher, M.D., an interventional radiologist with extensive experience in breast imaging and breast biopsy. Dr. Fisher and his team developed HydroMARK to provide physicians with a long-term ultrasound visible breast biopsy marking alternative. Long-term ultrasound visibility provides physicians with the option to eliminate a procedural step that can reduce the anxiety and pain of traditional breast cancer treatment.

The acquisition of HydroMARK is the latest in a series of product additions by Devicor, including the addition of the Mammotome MammoTestTM stereotactic table, and a new distribution agreement with Faxitron on their CoreVision®, core specimen radiography system. These complement recent internally developed products, Mammotome revolve® and Mammotome elite®. HydroMARK is currently available in most of North and South America, Europe and parts of Asia.

"As a company, our commitment to advancing the accurate diagnosis and treatment of breast cancer has never wavered," says Daulton. "We continue to look for technologies that complement our flagship brand, Mammotome® - the global leader in breast biopsy, as we build our innovative and market-leading organization."

About Devicor® Medical Products, Inc.
Devicor Medical Products, headquartered in Cincinnati, Ohio, has more than 400 employees around the globe. The company is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Devicor’s product portfolio includes the world-renowned Mammotome® Breast Biopsy System, neo2000® Gamma Detection System (GDS) and tissue markers (MammoMARK, MicroMARK®II, and CorMARK) used in breast disease diagnostic sampling and management. These products are sold in more than 50 countries around the world. Since its introduction in 1995, more than 4 million women have had a minimally invasive breast biopsy in stereotactic, ultrasound or MRI-guidance imaging using the Mammotome® Breast Biopsy System. For more information, please visit www.devicormedical.com or www.mammotome.com.

About GTCR
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.

Download PDF

May 1st, 2014
FAXITRON AND DEVICOR MEDICAL PRODUCTS ANNOUNCE NEW DISTRIBUTION AGREEMENT

Devicor® Medical Products, Inc. is now a distributor of Faxitron’s CoreVision®, core specimen radiography system

Cincinnati, Ohio – May 01, 2014– Devicor® Medical Products, Inc. (Devicor), a portfolio company of GTCR, a leading private equity firm, and Faxitron® Bioptics, LLC are pleased to announce a new distribution agreement for Faxitron’s CoreVision® in the United States and abroad. CoreVision® verifies the presence of micro-calcifications in core biopsies, rapidly confirming a successful biopsy procedure directly in the stereotactic biopsy suite.

Faxitron’s CoreVision® is sold to breast radiologists, breast surgeons and clinicians around the world. The use of purpose-built, point-of-care specimen radiography like Faxitron’s CoreVision®, is to minimize patient discomfort through shorter procedure times that also allow for workflow efficiencies and more room turns.

"Our strategy is focused on providing best-in-class technology that increases the accuracy of breast cancer detection while facilitating more efficient clinical practice," said Devicor CEO Tom Daulton. "Faxitron’s CoreVision® is perfectly aligned with our mission, and is highly complementary with our current products, including Mammotome revolve® and the Mammotome MammoTestTM stereotactic biopsy table."

The agreement includes the newly co-branded Mammotome CoreVision® within the United States, with impending distribution in other countries in Europe and Asia.

"This joint venture is one of the most exciting events in our company’s history," said Faxitron CEO Paul Murtagh. "Together, our combined market presence will help us reach more hospitals and breast centers and provide the equipment needed to redefine procedural efficiency."

About Faxitron® Bioptics, LLC
Faxitron is the world’s largest and only fully vertically integrated, dedicated cabinet x-ray company. With an installed base of over 7,000 systems in medical facilities and scientific and industrial research laboratories around the globe, Faxitron is the pioneer and industry standard in cabinet x-ray systems for specimen radiography, research, and NDT applications. For more than 40 years, Faxitron has defined cabinet x-ray by developing x-ray sensor technology and innovative systems to meet the evolving needs of our customers.

About Devicor® Medical Products, Inc.
Devicor Medical Products, headquartered in Cincinnati, Ohio, has more than 400 employees around the globe. The company is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Devicor’s product portfolio includes the world-renowned Mammotome® Breast Biopsy System, neo2000® Gamma Detection System (GDS) and tissue markers (MammoMARK, MicroMARK®II, and CorMARK) used in breast disease diagnostic sampling and management. These products are sold in more than 50 countries around the world. Since its introduction in 1995, more than 4 million women have had a minimally invasive breast biopsy in stereotactic, ultrasound or MRI-guidance imaging using the Mammotome® Breast Biopsy System. For more information, please visit www.devicormedical.com or www.mammotome.com.

About GTCR
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.

Download PDF

December 6th, 2012
DEVICOR ANNOUNCES FDA APPROVES Mammotome® revolve Biopsy System

Featuring patented DualVac technology and patented specimen management system

+Read More >Download PDF

April 19th, 2012
DEVICOR LAUNCHES NEW TETHERLESS VACUUM-ASSISTED BIOPSY SYSTEM

FDA approves Mammotome® elite Biopsy System; first device of its kind with TruVac vacuum technology

+Read More >Download PDF

March 12, 2012
DEVICOR® MEDICAL PRODUCTS, INC. ENTERS INTO A DISTRIBUTION AGREEMENT WITH CARBON MEDICAL TECHNOLOGIES

Deal enhances tissue marker product line of Mammotome®, a division of Devicor

+Read More >Download PDF

November 25, 2011
MAMMOTOME MARKS KEY MILESTONES AS IT GROWS U.S. AND GLOBAL PRESENCE

Product development efforts drive innovation and growth; Company plans for new product launch in early 2012

+Read More >Download PDF

August 17, 2011
DEVICOR® MEDICAL PRODUCTS, INC. COMPLETES ACQUISITION OF NEOPROBE'S GAMMA DETECTION DEVICES

Deal Adds Key Building Block To Devicor's Growth Strategy

+Read More >Download PDF

May 25, 2011
DEVICOR® MEDICAL PRODUCTS, INC. AGREES TO ACQUIRE NEOPROBE'S GAMMA DETECTION DEVICES

Deal Adds Key Building Block To Devicor's Growth Strategy

+Read More >Download PDF